MORE | Spring 2024

Development of Biomimetic Nanoparticles for Smooth Muscle Dysfunction

Atherosclerosis remains a global factor in mortality and morbidity. As the disease progresses, plaque builds up within the arterial wall narrowing the lumen. Interventions such as angioplasty and stenting cause vascular injury which induces pathological phenotypes in smooth muscle cells (SMC), leading to neointima hyperplasia. This project addresses the challenge by developing a biomimetic nanodrug to inhibit the SMC pathology. It focuses on characterizing the physicochemical properties of the nanoparticles and evaluating their efficacy in suppressing SMC dysfunction. Successful completion of this project could pave the way for future in-vivo testing of the nano-drug in mitigating arterial stenosis following interventions.